How Much Do Mass Tort Leads Cost? A Budget Planning Guide for Law Firms

Every mass tort lead has a production cost behind it: the advertising spend required to put a qualifying claimant through screening, plus the work of building pages, writing creative, and operating the pipeline. Litigations with broad awareness cost less to advertise against, because large numbers of affected people already know something happened. Litigations involving obscure devices, quiet exposures, or long latency periods cost more, because the audience must be built from scratch.

Screening depth is the other driver. A lead screened against five criteria requires many more completed screenings than a lead screened against one, because most claimants wash out. The provider is pricing the effort to deliver a claimant who actually matches, not just a form submission. Understanding these two drivers explains most of the price differences you will see between vendors.

Cost per lead is easy to compare and nearly useless. A lead at a low price that fails criteria, never answers the phone, or has already signed with another firm costs the firm its full price plus the intake time wasted on it. A higher-priced lead that matches every criterion and signs is cheaper than it looks, because the comparison is not price, it is price per signed case.

This is the discipline that separates firms that profit from lead buying from firms that churn through vendors. Track every lead from delivery to outcome, compute what you paid for the leads that became signed cases, and judge each source and each vendor on that number. It is slower than comparing price lists, and it is the only comparison that reflects reality.

Two factors dominate the variation between litigations: audience size and screening strictness. A litigation affecting hundreds of thousands of people with a widely reported diagnosis can reach qualifying claimants at a lower production cost. A litigation affecting a smaller group, or one where the required diagnosis is uncommon, takes more advertising and more screenings to produce the same qualified lead.

There is also a practical difference between litigations that are active in the news and litigations that are not. Claimants who have already read about their situation convert faster and cheaper; claimants who are learning about the litigation for the first time from your ad need more education before they complete screening. Neither is better as a case. They simply cost different amounts to produce.

A provider's price bundles several work streams that the firm would otherwise have to run itself: media buying across search, social, and video; creative development and testing; landing page builds with compliant consent language; the screening operation; the delivery infrastructure; and the record-keeping that keeps each lead's source, timestamp, IP, consent, and answers on file.

When comparing vendors, ask which of these are included and which are extra. A lower price that excludes record-keeping or screening depth is not a lower price; it is a smaller product. The honest comparison is between providers delivering the same product: a claimant screened to your criteria, delivered exclusively, with a consent record that will hold up years later.

Shared leads cost less per lead and more per signed case. When a claimant is sold to several firms, every firm pays for leads whose best case was already taken by whichever firm called first. The discount is real; the outcome for most buyers is not. Firms that buy shared leads tend to spend more total money to sign the same number of cases.

Exclusive leads cost more per lead because the provider genuinely sells one lead once. The economics work out in the firm's favor when the lead quality is high: fewer wasted intake hours, no racing other firms to the phone, and a claimant who hears about their situation for the first time from your intake team. Lead Search Pros sells the leads from each campaign to one firm and never resells them.

A disciplined mass tort budget runs in phases. The test phase commits a defined portion of the budget, enough to produce a meaningful sample of qualified leads, with one question in mind: what share of delivered leads matches criteria and stays reachable? The scale phase follows only if the sample is good, increasing volume while watching the same measures. The steady-state phase settles the spend where cost per signed case stays acceptable.

The phase structure protects the firm from the two classic budget errors: spending the entire budget at launch on an untested claim, and abandoning a campaign after a slow first week before the intake lag clears. Decide the size of the test and the review dates before spending a dollar, and write them down.

Mass tort intake is patient by nature. Unlike an accident victim, a claimant in a mass tort has no emergency, so many good leads take multiple touches over days or weeks before they sign. That lag has a budget consequence: in the first weeks of a campaign, cost per signed case looks artificially high because the cases have simply not signed yet.

Firms that judge a campaign in its first ten days almost always misread it. The practical fix is to set expectations in writing at launch: weekly reviews look at delivery volume, qualification rate, and contact rate; monthly reviews look at cost per signed case. Give the campaign enough runway for the lag to clear before making a scale or stop decision.

The lag also rewards firms that keep a pipeline view of every delivered lead. A lead counted as lost after one voicemail is not lost; it is a case waiting for the fourth touch. Budget models that treat every non-signing lead after a week as waste overstate the cost of the campaign, so measure what a lead becomes after the full follow-up cadence has run, not after the first attempt.

For the same budget, a provider can usually deliver more leads screened against fewer criteria, or fewer leads screened against more. Neither is wrong. A firm with a large intake team and flexible criteria may prefer volume. A firm with limited intake capacity, or one accepting a narrow slice of a litigation, should pay for strict screening and receive fewer, better leads.

The mistake is drifting into the trade-off unconsciously. Decide which your firm needs before negotiating a package, and make the screening depth explicit in the agreement. The firm that knows its trade-off gets what it pays for; the firm that does not gets whatever the vendor found easiest to sell.

No screening operation is perfect. Some leads will turn out to be wrong numbers, duplicates, solicitors, or outside the agreed criteria. The vendor's replacement policy is therefore part of the real price: a lead whose defects are replaceable costs less than the same lead bought from a vendor with no policy.

Read the policy before you buy, not after the first bad lead. Lead Search Pros replaces any lead reported within 72 hours that turns out to be a wrong number, a duplicate, a solicitor, or outside your agreed criteria, at no cost. The policy is published on our lead policy page. Replacement leads protect the budget because they keep the denominator of your cost per signed case honest.

Lead Search Pros prices every campaign as an agreed package paid upfront, with no retainer and month-to-month terms with 30-day cancellation notice. Upfront payment is how the provider funds the advertising that produces the leads; the protections that matter to the firm are the replacement policy and the cancellation terms, not the payment timing.

The structure also keeps the accounting clean. The firm knows exactly what a package contains: which litigation, what screening, how many leads, and what happens if a lead is defective. There are no hour-by-hour billing surprises, no media pass-throughs to audit, and no minimums forcing spend the firm did not plan. When the terms are this plain, budget planning becomes arithmetic instead of negotiation.

To compare two vendors on cost, you need three numbers from each: the price per lead, the screening criteria a lead must match before delivery, and the replacement policy. A lower price with weaker screening and no replacement policy is a worse deal at any price. A higher price with strict screening and free replacements within a reporting window is usually the cheaper source of signed cases.

Also ask for the record: every lead should ship with the source page, timestamp, IP address, consent, and the claimant's answers. Vendors who cannot produce that record are passing compliance risk to your firm, which is a cost that shows up years later. The cheapest leads on the market are usually cheap for a reason the price list does not show.

One more comparison makes the picture complete: the sample. Ask each vendor to walk through two or three actual delivered leads with the identifying details removed, and look at the screening answers, the consent language, and the timestamps yourself. A price backed by a real sample is a number you can plan around. A price with no sample behind it is a promise, and promises do not sign cases.

Some pricing practices should end the conversation. Leads offered with no screening questions, or with screening so shallow that anyone with a pulse qualifies. Prices that change by the week without a written basis. Vendors who will not state in writing whether a lead is exclusive. Vendors with no replacement policy, or one that expires in a day. And any vendor who quotes outcomes, settlement amounts, or guaranteed results as part of the pitch, which is both a marketing red flag and a compliance one.

None of these red flags means the vendor is dishonest, but all of them mean the firm cannot compute what it is actually buying. A vendor confident in its product welcomes the three questions from the previous section, because strict screening and a published replacement policy are exactly what it sells.

Bring these questions to any provider conversation. What are the exact screening questions for this litigation, and can I see them before I buy? Is the lead exclusive to my firm, in writing? What does each lead include, and where is the consent record stored? What is the replacement policy, how long is the reporting window, and is it published? What are the payment and cancellation terms? And how do you measure and report qualification rate over time?

The vendor's answers tell you more than its price. Specific, confident, written answers mean you can plan. Vague answers mean you will be renegotiating after the first month, which is the most expensive way to run a campaign.

You do not need a spreadsheet full of invented numbers to plan a budget; you need a framework. Set the total amount you are willing to commit to the litigation. Reserve a defined first phase as the test, sized to produce a meaningful sample of leads. Define in advance what qualification rate and contact rate you need to see before scaling. Define the monthly review that computes cost per signed case. And define the stop conditions in advance, so pausing is a decision you make on schedule rather than in frustration.

Every number in that framework is the firm's to set based on its own capacity and case economics. The framework's value is that it forces the decisions to happen before the spend, when judgment is cheap and calm, instead of during the campaign, when every week feels urgent.

Our approach is straightforward: the package is agreed upfront, with the litigation, the screening built from your written criteria, the volume, and the replacement terms all in the agreement. Payment is upfront, there is no retainer, terms are month-to-month with 30-day cancellation notice, and leads reported as defective within 72 hours are replaced free.

That structure exists so the budget conversation happens once, in plain terms, before launch. If you want to know what a campaign for your litigation would involve, book a call and we will walk through the criteria, the screening, and the package together.